The predictors of the efficacy of pharmacological cardioversion with class III antiarrhythmic drug - nibentan in patients with persistent atrial fibrillation

被引：0
|
作者：
Bregvadze, I. [1 ]
Maykov, E. [2 ]
Sokolov, S. [2 ]
Golitsyn, S. [2 ]
Rozenshtraukh, L. [2 ]
Chazov, E. [2 ]
Pagava, Z. [1 ]
机构：
[1] Ctr Vasc & Heart Dis, Cardiol, Tbilisi, Georgia
[2] Cardiol Res & Prod Ctr, Clin Electrophysiol, Moscow, Russia
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6383
引用
收藏
页码：1374 / 1374
页数：1
相关论文
共 50 条
  • [1] The efficacy and safety of new class III antiarrhythmic drug nibentan for cardioversion in patients with persistent atrial fibrillation
    Bregvadze, I. N.
    Maykov, E. B.
    Sokolov, S. F.
    Golitsyn, S. P.
    Rozenshtraukh, L. V.
    Chazov, E. I.
    EUROPEAN HEART JOURNAL, 2006, 27 : 887 - 887
  • [2] Nibentan - A drug for pharmacological cardioversion of persistent atrial fibrillation
    Shubik, YV
    Medvedev, MM
    Rivin, AE
    KARDIOLOGIYA, 2005, 45 (03) : 19 - 23
  • [3] Combined administration of new class III antiarrythmic drug nibentan and magnesium sulfate for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter
    Bregvadze, I. N.
    Maykov, E. B.
    Sokolov, S. F.
    Golitsyn, S. P.
    Rozenshtraukh, L. V.
    Chazov, E. I.
    EUROPEAN HEART JOURNAL, 2007, 28 : 403 - 403
  • [4] Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter
    Maykov, E. B.
    Yuricheva, Yu. A.
    Mironov, N. Yu.
    Sokolov, S. F.
    Golitsyn, S. P.
    Rozenshtraukh, L. V.
    Chazov, E. I.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (01) : 38 - 48
  • [5] Clinical experience with novel antiarrhythmic class III drug nibetnan for cardioversion of persistent atrial fibrillation
    Shubik, YV
    Platonov, PG
    Medvedev, MM
    Rivin, A
    EUROPEAN HEART JOURNAL, 2004, 25 : 492 - 492
  • [6] Efficacy and safety of nibentan for cardioversion in patients with persistent atrial fibrillation with and without amiodarone therapy
    Berkowitsch, A.
    Rivin, A.
    Medvedev, M.
    Zaltsberg, S.
    Shubik, I.
    EUROPEAN HEART JOURNAL, 2006, 27 : 888 - 888
  • [7] Efficacy of a New Class III Drug Niferidil in Cardioversion of Persistent Atrial Fibrillation and Flutter
    Maykov, Evgeny B.
    Yuricheva, Yulia A.
    Mironov, Nikolay Yu
    Sokolov, Sergey F.
    Golitsyn, Sergey P.
    Rosenshtraukh, Leonid V.
    Chazov, Evgeny I.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (03) : 247 - 255
  • [8] Effects of a new class III antiarrhythmic drug nibentan in a canine model of spontaneous atrial fibrillation
    Fedorov, VV
    Beloshapko, GG
    Yushmanova, AV
    Sharifov, OF
    Rosenshtraukh, LV
    EUROPEAN HEART JOURNAL, 2003, 24 : 391 - 391
  • [9] The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration
    Bregvadze, I. N.
    Maykov, E. B.
    Bildinov, O. A.
    Kratskina, T. L.
    Klimenko, Yu. L.
    Smirnova, M. Yu.
    Sokolov, S. F.
    Golitsyn, S. P.
    Rozenshtraukh, L. V.
    Chazov, E. I.
    KARDIOLOGIYA, 2007, 47 (03) : 48 - 55
  • [10] Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation
    Fedorov, VV
    Sharifov, OF
    Beloshapko, GG
    Yushmanova, AV
    Rosenshtraukh, LV
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 36 (01) : 77 - 89
12345